Valeant Pharma (VRX) Reports Q2 EPS of $1.91
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Financial Fact:
Total costs and expenses: 183.41M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Financial Fact:
Total costs and expenses: 183.41M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Valeant Pharma (NYSE: VRX) reported Q2 EPS of $1.91, versus $1.34 reported last year. Revenue for the quarter came in at $1.99 billion, versus $1.06 billion reported last year.
For earnings history and earnings-related data on Valeant Pharma (VRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Robinhood plans $2B convertible notes offering due 2029
- Middleby board approves spin-off of food processing unit Midera
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
